SERMO unveils first global physician-to-physician drug ratings tool
SERMO, the largest global social network for physicians with 650,000 members worldwide, has announced the groundbreaking new "Drug Ratings" tool. Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. With more than a quarter million ratings and 20,000 comments from doctors worldwide to date in the beta release, the Ratings platform is quickly becoming the largest global database of physician feedback on drugs.
Read more ...
Grants4Apps Accelerator and new Dealmaker now open for submissions
The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.
Read more ...
LEO Innovation Lab CEO wins eyeforpharma Customer Innovator Award
LEO Innovation Lab is proud to announce that our CEO Kristian Hart-Hansen has won the eyeforpharma Customer Innovator Award. Kristian has spearheaded the growth of the LEO Innovation Lab since it's conception in 2015 with just six team members, to a thriving incubator of over 80 people and 15 projects today. The lab was established by LEO Pharma as an independent initiative to focus on using digital innovation to help individuals manage chronic skin conditions.
Read more ...
Mindprint implements market-leading automation solution for Ockham Oncology
Mindprint Inc. and Ockham Development, Inc. have implemented an innovative automation software system to help the global CRO manage trials efficiently to ensure a more focused approach to its core oncology mission.
Read more ...
Astellas and Ambrx initiate collaboration for discovery and development of antibody drug conjugates for oncology
Astellas Pharma Inc. (Tokyo: 4503, "Astellas") entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.
Read more ...
Luqa Pharmaceuticals and Stratpharma enter into an exclusive agreement
Luqa Pharmaceuticals announced today that it has entered into an exclusive agreement with Stratpharma AG of Switzerland to promote, sell, and distribute Strataderm®, in the People's Republic of China.
Read more ...
Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
Sanofi and Astellas Pharma Inc. announced that the two companies agreed to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc., a joint company of Sanofi and Astellas.
Read more ...
SERMO, the largest global social network for physicians with 650,000 members worldwide, has announced the groundbreaking new "Drug Ratings" tool. Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. With more than a quarter million ratings and 20,000 comments from doctors worldwide to date in the beta release, the Ratings platform is quickly becoming the largest global database of physician feedback on drugs. 
LEO Innovation Lab is proud to announce that our CEO Kristian Hart-Hansen has won the eyeforpharma Customer Innovator Award. Kristian has spearheaded the growth of the LEO Innovation Lab since it's conception in 2015 with just six team members, to a thriving incubator of over 80 people and 15 projects today. The lab was established by LEO Pharma as an independent initiative to focus on using digital innovation to help individuals manage chronic skin conditions. 
Astellas Pharma Inc. (Tokyo: 4503, "Astellas") entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.